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Abstract: The action of botulinum neurotoxins (BoNTs) at the neuromuscular junction has 
been extensively investigated and knowledge gained in this field laid the foundation for the 
use  of  BoNTs  in  human  pathologies  characterized  by  excessive  muscle  contractions. 
Although  much  more  is  known  about  the  action  of  BoNTs  on  the  peripheral  system, 
growing  evidence  has  demonstrated  several  effects  also  at  the  central  level.  Pain 
conditions,  with  special  regard  to  neuropathic  and  intractable  pain,  are  some  of  the 
pathological states that have been recently treated with BoNTs with beneficial effects. The 
knowledge of the action and potentiality of BoNTs utilization against pain, with emphasis 
for  its  possible  use  in  modulation  and  alleviation  of  chronic  pain,  still  represents  an 
outstanding challenge for experimental research. This review highlights recent findings on 
the effects of BoNTs in animal pain models. 
Keywords: botulinum toxin; SNARE; pain; animal model; analgesia; inflammatory pain; 
chronic pain; peripheral sensitization; central sensitization; retrograde axonal transport  
 
1. Historical Overview: From Sausages to Universal Drug 
Botulinum neurotoxins (BoNTs) are produced by anaerobic bacteria of the genus Clostridium and 
are the most poisonous biological substances known [1,2]. BoNTs are responsible for botulism, a 
neuroparalytic  syndrome  characterized  by  flaccid  paralysis,  originating  in  the  peripheral  nervous 
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system, and by dysfunctions of the autonomic nervous system [3–6]. In food borne botulism, the most 
common form of botulism, BoNTs are ingested with food in which spores have germinated and the 
organism has grown. Food-borne botulism has accompanied mankind since the beginning (see [7] for 
extensive  review).  At  the  end  of  the  18th  century,  some  well-documented  outbreaks  of  sausage 
poisoning in Wü rttemberg, Southern Germany, prompted early systematic botulinum toxin research. 
Between 1817 and 1822, the German poet and district medical officer Justinus Kerner published the 
first accurate and complete description of the symptoms of food-borne botulism. He did not succeed in 
defining the suspected biological poison that he called ―sausage poison‖ or ―fatty poison‖; however, he 
developed the idea of a possible therapeutic use of the toxin. In 1895, Emile Pierre van Ermengem, 
Professor of bacteriology at the University of Ghent, following a botulism outbreak after a funeral 
dinner with smoked ham in the small Belgian village of Ellezelles, discovered the pathogen anaerobic 
gram  positive  bacterium  Clostridium  botulinum.  The  bacterium  was  so  called  because  of  its 
pathological association with the sausages (Latin word for sausage = botulus).  
It was not until the middle of 20th century that BoNTs were used as therapeutic drugs in medicine. 
Research began when Dr. Edward J. Schantz and his colleagues were able to purify botulinum toxin 
serotype A (BoNT/A) into crystalline form. In 1953, the physiologist Dr. Vernon Brooks discovered 
that  the  injection  of  small  amounts  of  BoNT/A  into  a  hyperactive  muscle  blocked  the  release  of 
acetylcholine (ACh) from  motor nerve endings, causing temporary  ―relaxation‖.  In the 1960s,  the 
ophthalmologist  Dr.  Alan  B.  Scott  started  treating  monkeys  with  BoNT/A,  theorizing  that  its  
muscle-relaxing effects might help in the treatment of crossed eyes (or strabismus). In the 1980s, Alan 
Scott  introduced  the  use  of  BoNT/A  as  an  alternative  to  conventional  surgery  to  treat  human 
strabismus. After these pioneering studies, therapeutic applications of BoNT/A were extended to a 
wide variety of neurological disorders associated to spasmodic muscle contractions, for example, the 
spasmodic  torticollis,  blefarospams,  facial  emispams,  and  dystonia  [8].  Nowadays,  the  clinical 
indications for BoNT/A are constantly growing, ranging from treatment of overactive skeletal and 
smooth muscles, to management of hypersecretory and painful disorders such as migraine, trigeminal 
neuralgia and the myofascial pain syndrome [9–11].  
This review is focused on studies in which BoNTs, mainly BoNT/A, were used as pharmacological 
treatment against pain in animal models.  
2. Cellular Mechanism: General Considerations and Different BoNTs Serotypes 
From  the  plethora  of  toxins  produced  by  Clostridium  botulinum,  only  toxins  whose  action  is 
restricted to the nervous system, such as BoNTs, are strictly defined as neurotoxins. Other toxins, such 
as botulinolisin, toxin-C2, exoenzyme-C3, which target different type of cells, mostly non-neuronal, 
are  not  included  in  the  BoNTs  family.  Seven  different  serotypes  of  BoNTs  have  so  far  been 
characterized  (A-G),  and  these  serotypes  are  active  on  many  different  types  of  vertebrates  [3,4]. 
BoNTs  are  secreted  as  multimolecular  complexes  together  with  non  toxic  accessory  proteins 
(emagglutinins) that do not contribute to the paralyzing effects of BoNTs but protect them from the 
passage  through  the  acidic  and  proteolytic  environment  of  the  stomach  after  the  ingestion  of  
spore-contaminated food [12,13].  Toxins 2010, 2  
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BoNTs  are  proteins  of  about  1,300  amino  acids  and  consist  of  three  domains  of  similar  size  
(50  kDa).  The  NH2-terminal  domain,  which  is  named  L-chain  (L  =  light)  domain,  is  a  zinc 
endopeptidase that represents the catalytic domain expressing the protease activity. The other two 
domains,  which  are  covalently  bound  to  form  the  H-chain  (H  =  heavy),  are  the  central  domain, 
responsible  for  the  membrane  translocation  of  the  L-chain  into  the  neuronal  cytosol,  and  the  
COOH-terminal  domain,  which  consists  of  two  equally  sized  subdomains,  responsible  for  the 
neurospecific binding [14–16]. 
The  cellular  action  of  BoNTs  occurs  as  a  four-step  mechanism:  (i)  binding  of  BoNTs  on  the 
neuronal presynaptic membrane, via interaction with gangliosides, synaptic vesicle protein 2 and/or 
synaptotagmin, depending on the serotype [16–18]; (ii) internalization of BoNTs via endocytosis of  
the  BoNTs-receptor  complex  inside  the  neurons;  (iii)  translocation  of  BoNTs  L-chain  from 
endocytosed vesicle to the neuronal cytosol; and, finally, (iv) zinc-endopeptidase activity on cellular 
targets [13,14,25]. Intracellular targets of BoNTs are three proteins involved in neuroexocytosis of the 
neurotransmitter  synaptic  vesicles.  These  proteins  are:  SNAP-25  (synaptosomal  associated  protein  
of 25 kDa), VAMP (vesicle associated membrane protein), also called synaptobrevin, and sintaxin. All 
these proteins are involved into assembly of the SNARE (soluble N-ethylmaleimide-sensitive factor 
attachment protein receptors) protein core complex, which is fundamental for correct docking and 
fusion of neurotransmitter vesicles with neuronal membranes [13–20]. The peculiar characteristic of 
BoNTs resides in their high affinity for one of the three SNARE proteins: SNAP-25 is cleaved by 
BoNT/A (the serotype most commonly used in clinical practice), /E and /C; VAMP/sinaptobrevin is 
the target of BoNT/B (another serotype used in clinic), /D, /F and /G; and sintaxin is cleaved only by 
BoNT/C. The cleavage of one of these proteins is sufficient to prevent the correct assembly of the 
SNARE core complex and the consequent fusion of synaptic vesicles with the neuronal presynaptic 
membrane,  thus  inhibiting  the  neurotransmitter  release  [19,20].  This  effect  is  reversible,  and  the 
duration of action is dependent on the serotype. Further details on binding, internalization and mode of 
action of the different BoNTs serotypes can be found in other reviews [21–26].  
3. Beyond Muscular Effects: Involvement of Molecules Modulating Pain  
Studies  on  the  pathophysiology  of  botulism  revealed  that  neuromuscular  paralysis  is  due  to 
selective  inhibition  of  evoked  ACh  release  from  cholinergic  nerve  endings  at  the  skeletal 
neuromuscular  junction  [1].  This  canonical  effect  of  BoNTs  gave  the  opportunity  to  use  them  as 
therapeutic  agents  in  a  variety  of  neurological  disorders  due  to  hyperfunctionality  of  cholinergic 
terminals [8]. However, BoNTs cannot be considered exclusively as ‗cholinergic‘ toxins. Though they 
act preferentially on nerve terminals between motoneurons and muscle fibers, BoNTs can also block 
the neural transmission at other peripheral synapses, cholinergic or not [9]. This has indirectly been 
proved  also  by  symptoms  observed  during  botulinal  neuromuscular  paralysis,  where  autonomic 
nervous system dysfunction (parasympathetic, i.e., cholinergic, and sympathetic, i.e., adrenergic and 
noradrenergic) coexists with neuro-motor alterations [4,13].  
Extensive in vitro and in vivo studies demonstrated that BoNTs (mainly BoNT/A) are able to block 
the Ca
2+-evoked release of neurotransmitters, other than ACh [27]. As for examples, in vitro studies 
demonstrated  that  BoNTs  inhibit  various  neurotransmitters‘  release,  including  glutamate,  GABA, Toxins 2010, 2  
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aspartate, catecholamine, and noradrenaline,  from  cerebral  synaptosomes,  chromaffin cells,  central 
neurons  and  hippocampal  slice  cultures  [28–38].  In  vivo  studies,  mainly  using  microdialysis 
techniques, demonstrated that  BoNTs block both  dopamine and monoamine release under various 
conditions [39–42]. Moreover, BoNTs block glutamate release also from non-neuronal cells, such as 
astrocytes  [43–45].  Finally,  there  are  many  evidences  in  literature  that  BoNTs  are  able  to  block  
the  release  not  only  of  classical  neurotransmitters  but  also  of  neuropetides,  such  as  Substance  P  
(SP) [46–49] and calcitonin gene-related peptide (CGRP) [50–55]; neuropeptides whose role in pain 
modulation is known. These latter findings gave strong input in searches for alternative therapy against 
trigeminal neuralgia and various types of headache and migraine—neurological diseases where SP and 
CGRP release often act as a trigger point to exacerbate disease attacks. In these pathologies, BoNT/A 
probably exerts analgesia by blocking the neuropeptides‘ release at the nociceptive nerve endings. 
Some  encouraging  results  have  been  obtained  in  humans  [56,57].  The  effect  of  BoNT/A  in  
tension-type  headache,  chronic  daily  headache,  and/or  migraine  is  not  further  considered  in  the  
present review.  
BoNT/A is effective in relieving pain in spastic and non-spastic muscle conditions in humans. This 
analgesic  effect  has  generally  been  attributed  to  muscular  relaxation.  Notwithstanding,  there  are 
reports  in  the  literature  stating  that  patients  experience  pain  relief  shortly  after  BoNT/A  
treatment [58,59], i.e., before of any muscle-relaxing action of the toxin, or that the pain relief is still 
maintained after muscle power returned to normality [60]. These results suggest that the analgesia 
attributed to BoNT/A may be due to more complex mechanisms than the simple muscular relaxation. 
In such cases, the pain relief cannot be ascribed to abolition of those factors, such as muscle tone, 
excessive muscle contraction and spasms, which are due to muscle hyperactivity [61]. In  the next 
sections, we will discuss the evidences from animal models in favor of an analgesic action of BoNTs, 
with  particular  emphasis  on  pain  not  directly  related  to  abnormal  muscle  hyperactivity,  such  as 
inflammatory and neuropathic pain. Animal model studies have been mainly performed with BoNT/A 
and /B and have been conducted by using the 150 kDa purified toxin or equivalent commercial products.  
In the following, we will indicate BoNT/A, or /B, indifferently from which preparation has been 
actually utilized. 
4. Animal Models Predicting the Therapeutic Use of BoNTs against Pain 
Generally, pain is divided into nociceptive and pathological pain. Nociceptive pain is caused by the 
sustained  activation  of  peripheral  nociceptors  in  response  to  peripheral  tissue  injury  and  can  be 
classified as somatic or visceral pain according to where the pain arises. The extent of nociceptive pain 
normally reflects the extent of tissue damage and it disappears when the origin of nociceptive stimuli 
disappears. On the other hand, pathological pain often evolves toward a chronic condition in which 
pain exceeds the extent of tissue damage. Independently from the organs or tissues involved, chronic 
pain may be a consequence of either inflammatory processes (for example, rheumatoid arthritis in 
humans)  and/or  injury  to  the  nervous  system,  both  peripheral  (PNS)  (for  example,  postherpetic 
neuralgia) and central (CNS) (for example, spinal cord injury) nervous system, which is commonly 
known  as  neuropathic  pain.  A  common  feature  of  pain-related  mechanisms  is  the  activation  of 
sensitization processes, plastic changes in PNS and CNS (adaptative or pathological) that lead to an Toxins 2010, 2  
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enhanced response and/or decreased threshold to nociceptive stimuli. For example, under neuropathic 
pain conditions, both hyperalgesia (an exaggerated pain perception in response to a painful stimulus) 
and  allodynia  (the  perception  as  painful  of  a  stimulus  that  does  not  usually  provoke  pain)  are 
commonly developed. In basic science, many animal pain models have been developed in order to 
mimic  human  pain  conditions.  In  the  next  paragraphs  of  this  section,  an  overview  of  the  studies 
involving the use of BoNTs in animal pain models will be presented and relevant results discussed.  
4.1. Peripheral Inflammatory Pain Model 
A direct involvement of BoNTs in mechanisms involved in pain modulation was first described by 
Cui et al. [62], who analyzed the effects of BoNT/A in formalin-induced inflammation as an animal 
model of inflammatory pain. Formalin-induced inflammatory pain model is extensively used for the 
evaluation  of  possible  analgesic  effects  of  test  compounds.  It  is  performed  by  injecting  a  diluted 
formalin solution into one hindpaw of rats, or mice, and by recording the formalin-evoked behaviors. 
The  most  characteristic  behavioral  response  of  rodents  to  formalin  injection  is  the  licking  of  the 
injected  paw.  This  response  appears  biphasic,  with  an  early  phase  of  extensive  licking  due  to 
peripheral  sensitization  of  nociceptors,  followed  by  an  interphase  with  almost  absence  of  licking 
activity  due  to  activation  of  inhibitory  descending  pathways,  and  finally  by  a  second  phase  of 
extensive licking, which essentially reflects the progression of peripheral inflammation together with 
the activation of central sensitization processes [63]. Cui et al. [62] found that a single peripheral 
subcutaneous injection of BoNT/A was able to reduce licking activity during the second phase, in a 
dose-dependent manner, with the absence of any obvious muscle weakness at doses below 30 U/kg. 
BoNT/A,  administered  at  different  time  intervals  prior  to  formalin  testing,  induced  long-lasting 
analgesic effects, starting within the first 24 hours and lasting at least 12 days, the latest time point 
tested.  The  reduction  of  licking  activity  was  accompanied  by  the  inhibition  of  formalin-induced 
peripheral release of glutamate in the rat paw, and by the reduction of paw edema that is usually 
observed  as  a  consequence  of  neurogenic  inflammatory  processes.  This  latter  effect  suggests  that 
BoNT/A  may  reduce  not  only  the  release  of  glutamate,  but  also  of  SP  and  CGRP  (not  directly 
measured  by  the  authors),  involved  in  SP-mediated  plasma  extravasation  and  CGRP-mediated 
vasodilatation, respectively. Interestingly, BoNT/A did not reduce the initial phase of licking behavior 
and  thermal  sensitivity,  indicating  no  effects  of  BoNT/A  injection  on  acute  pain.  The  authors 
postulated that BoNT/A is able to exert analgesic effects on formalin-induced inflammatory pain by 
inhibiting  the  peripheral  stimulation-induced  release  of  neurotransmitters,  such  as  glutamate,  and 
probably also of the neuropeptides SP and CGRP. Under this view, the analgesic activity of BoNT/A 
has been considered as a consequence of the inhibition of peripheral sensitization, resulting in indirect 
reduction of central sensitization processes [64,65]. 
Luvisetto et al. in mice [66] have essentially confirmed results of Cui et al. in rats [62]. These 
authors extended the analysis of BoNTs on formalin-induced inflammatory pain by considering for the 
first time the central (intracerebroventricular) versus peripheral (subcutaneous into hindpaw) effects. 
Moreover,  they  investigated  two  BoNTs  serotypes,  namely  BoNT/A  and  BoNT/B.  The  authors 
demonstrated that pre-treatment (3 days) with BoNT/A is able to reduce the second phase of formalin 
independently  from  the  route  of  administration,  demonstrating  that  BoNT/A  may  act  not  only Toxins 2010, 2  
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peripherally but also at the central level. On the contrary, BoNT/B did not reduce licking activity and, 
when centrally injected, had a hyperalgesic effect on the interphase of the formalin test. These results 
indicate  a  different  mechanism  of  action  of  BoNTs,  depending  on  the  serotype  and  route  of 
administration, and suggest that BoNT/A and BoNT/B are not interchangeable based on simple dose 
ratio, a point that is extremely important to take into account in a therapeutic perspective. Moreover, 
these observations were fundamental for the comprehension of the mechanism involved in the action 
of BoNTs: BoNT/A and BoNT/B may interact with inhibitory and/or excitatory systems in modulating 
persistent inflammatory pain. The different effects of the two serotypes may reflect differences in the 
expression  of  receptors  and  cellular  targets  of  BoNT/A  and  BoNT/B  (i.e.,  SNAP-25  and 
VAMP/synaptobrevin,  respectively),  as  well  as  in  the  expression  of  these  targets  into  different 
neuronal populations. 
A series of studies [67–70] showed that the vesicle recycling in hippocampal glutamatergic neurons 
is blocked by BoNT/A and BoNT/B while the same processes in hippocampal GABAergic neurons are 
blocked by BoNT/B but not by BoNT/A. Staining with various antibodies directed against SNAP-25 
reveals the specific presence of this protein in glutamatergic neurons, while GABAergic neurons lack 
immunoreactivity  for  SNAP-25.  In  contrast,  staining  with  antibodies  directed  against  SNAP-23,  a 
homolog of SNAP-25, shows its presence in both glutamatergic and GABAergic neurons. BoNT/A 
does not cleave SNAP-23 and this explains why BoNT/A is not able to block GABAergic neurons. On 
the other hand, BoNT/B acting on VAMP/synaptobrevin—another protein of the SNARE complex—is 
able to block GABAergic neurons. Considering all these pieces of evidence, the effect of BoNT/B on 
the interphase of the formalin test could be partially ascribed to a functional block of GABA inhibition 
on the primary afferent fibers in spinal dorsal horn.  
The  study  on  the  analgesic  effects  of  BoNT/A  on  inflammatory  pain  was  not  restricted  to  
formalin-induced pain and inflammation but was extended also to other models of inflammatory pain, 
such as that induced by carrageenan and capsaicin. Peripheral application of carrageenan or capsaicin 
produces hypersensitivity to thermal and mechanical stimuli as a consequence of inflammation due to 
injected chemicals irritants. Carrageenan promotes inflammation by activating proinflammatory cells 
and the resulting inflammatory edema is more extensive than edema induced by formalin. It causes 
hyperalgesia by promoting the peripheral release of mediators such as SP, glutamate, prostaglandins, 
histamine  and  serotonin,  as  well  as  release  of  glutamate,  aspartate,  SP,  CGRP,  nitric  oxide,  and 
prostaglandin E2 (PGE2) in the dorsal horn of lumbar spinal cord. On the other hand, capsaicin excites 
sensory neurons directly by acting on vanilloid receptors type 1 (VR-1), mostly expressed on C-fibers. 
VR-1 receptors are present on nerve fibers containing SP and CGRP that are released from nerve 
terminals  after  capsaicin  application.  Bach-Rojecky  and  Lacković  [71]  found  that  pre-treatment  
(6  days)  with  BoNT/A  significantly  reduced  or  completely  abolished  the  enhanced  sensitivity  to 
mechanical and thermal stimuli provoked by peripheral carrageenan or capsaicin injections in rats, 
demonstrating the efficacy of peripheral BoNT/A pretreatment on the pain component of inflammatory 
process  in  experimental  animals.  In  contrast  with  Cui  et  al.  [62],  BoNT/A  had  no  effect  on  the 
carrageenan-induced  paw  edema.  Following  this  last  observation,  in  another  study,  Back-Rojecky  
et al. [72] analyzed if the analgesic effect of BoNT/A on carrageenan- and capsaicin-inflammatory 
pain was directly due to the anti-nociceptive effect or indirectly due to the anti-inflammatory effect. 
The  authors  confirmed  that  pre-treatment  with  the  same  dose  of  BoNT/A  effective  in  reducing  Toxins 2010, 2  
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pain [71], had no effect on the size of carrageenan-induced paw edema, measured as paw volume and 
weight, or on the capsaicin-induced plasma extravasations (PE), measured by Evans blue as a marker 
of  protein  leakage.  From  this  finding,  they  concluded  that  BoNT/A  does  not  have  a  significant  
anti-inflammatory  effect  on  the  inflammation  induced  by  capsaicin  and  carrageenan,  indicating  a 
possible dissociation between the effect of BoNT/A on pain and on inflammation: only the former was 
affected by BoNT/A through the inhibition of the release of neurotransmitters from the peripheral 
endings of sensory nerves. Similar results were obtained also by Favre-Guilmard [73], who reported 
that BoNT/A was not able to reduce carrageenan edema, indicating that the antihyperalgesic effects of 
BoNT/A are independent of an anti-inflammatory activity related to increased vascular permeability 
and adherence/infiltration of inflammatory cells. On the contrary, Carmichael et al. [74] evidenced 
contrasting results on the anti-inflammatory effects of BoNT/A on neurogenic inflammation. These 
authors found that peripheral  subcutaneous  application of  BoNT/A reduced vasodilatation and  PE 
evoked by saphenous nerve stimulation or topical administration of capsaicin in the rat hindpaw skin, 
while it had no effect on SP-induced PE or CGRP-induced vasodilatation.  
Although some controversies appear to be still unsolved, studies presented in this paragraph are 
clearly  in  favor  of  BoNT/A  as  a  powerful  drug  against  inflammatory  pain  and  future  research  is 
necessary to better elucidate the mechanisms involved.  
4.2. Visceral Pain Model  
The  effect  of  BoNTs  on  visceral  pain  models  has  not  been  extensively  studied.  However,  the 
efficacy of BoNTs on relieving visceral pain has been analyzed in models mimicking pain symptoms 
due to lower urinary tract disorder in humans, such as that due to bladder hyperactivity and prostatitis. 
It  was  observed  that  intravesicular  administration  of  BoNT/A  produced  analgesia  against  acetic  
acid-induced bladder pain in rats by inhibiting the CGRP release from afferent nerve terminals [75].  
In another model, namely the cyclophosphamide-induced cystitis in the bladder of rats [76], BoNT/A 
inhibited  the  cyclooxygenase  2  (COX-2)  and  the  prostaglandin  EP(4)  receptor  expression  and 
suppressed  bladder  hyperactivity.  Moreover,  in  a  model  of  prostatitis,  obtained  by  intraprostatic 
capsaicin injection in rats, BoNT/A inhibited COX-2 expression and suppressed prostatic pain [77]. 
These studies in animal models (see also [54]) have paved the way toward an extensive therapeutic 
application  of  BoNT/A  in  clinical  treatment  of  human  disorder  related  to  lower  urinary  tract  
disorder [78]. 
4.3. Neuropathic Pain Model 
Neuropathic pain is a kind of chronic pain resulting from injury to the peripheral or central nervous 
system. Common examples of neuropathic pain include postherpetic neuralgia, diabetic neuropathy, 
complex regional pain syndrome, and pain associated with spinal cord injuries. Evidence for utility of 
BoNT/A  in  relieving  neuropathic  pain  symptoms  in  humans  was  first  reported  by  Klein  [79],  
who  demonstrated  the  effectiveness  of  BoNT/A  in  four  clinical  cases  in  alleviating  symptoms  of 
different  neuropathic  pain,  such  as  relapsing-remitting  multiple  sclerosis,  postherpetic  neuralgia, 
peripheral neuropathy, and severe tingling caused by herniation of cervical vertebrae at the level of C8. 
Since this initial observation, the action of BoNT/A in neuropathic pain has been also the focus of Toxins 2010, 2  
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experimental studies with the aim to better define its role as an analgesic and to investigate the neural 
mechanisms involved. 
Many  models  of  neuropathic  pain  are  currently  in  use  both  in  rats  and  mice  to  mimic  human 
peripheral  neuropathic  conditions  [80].  Depending  on  the  site  of  injury,  the  animal  models  of 
neuropathic pain are generally subdivided in central pain models (mainly based on spinal cord injury), 
peripheral nerve injury models (mainly injuries at the level of sciatic or spinal nerves), and peripheral 
neuropathy  induced  by  diseases  (postherpetic  neuralgia  and  diabetic  neuropathic  pain  models, 
chemotherapy-induced peripheral neuropathy models) [81–86]. Thermal and mechanical hyperalgesia 
as well as allodynia are hallmark properties of the experimental neuropathies. 
The effect of BoNT/A on neuropathic pain was first analyzed on the peripheral neuropathy induced 
by partial sciatic nerve transection in rats [87]. In this study, a single peripheral injection of BoNT/A 
was  sufficient  to  reduce  both  thermal  and  mechanical  hyperalgesia  without  any  apparent  muscle 
weakness. The effect of BoNT/A became evident five days after toxin application and lasted for more 
than 10 days. In accordance with previous observations in other pain models [62,66], the authors found 
that BoNT/A had no effects on thermal and mechanical thresholds of sham operated rats, confirming 
that BoNT/A per se does not change nociception. 
A second neuropathic pain model, used to test the efficacy of BoNT/A as an analgesic, was the 
L5/L6 spinal nerve ligation (SNL). In this study, Park et al. [88] considered allodynia rather than 
hyperalgesia as a behavioral parameter to assess the peripheral neuropathy. The authors found that a 
single peripheral administration (into the plantar skin of one hindpaw) of BoNT/A, dose-dependently 
reduced both mechanical and cold allodynia in SNL neuropathic rats.  
Finally, a third animal model of peripheral neuropathy, the chronic constriction injury (CCI) of the 
sciatic nerve, was considered in some recent studies [89–91]. In these studies, authors found that a 
single injection of BoNT/A into plantar surface of mice injured paws, performed at five or 12 days 
after CCI, markedly antagonized mechanical allodynia induced by CCI [Figure 1(A)]. This effect was 
already  evident  24  hours  after  BoNT/A  injection,  lasted  for  at  least  three  weeks,  and  was  
dose-dependent [Figure 1(B)]. Interestingly, differently from BoNT/A treatment post surgery, if the 
BoNT/A injection preceded (3 days) the CCI, the antiallodynic effect was absent. These later findings 
underline the difference to what is observed in inflammatory pain models where BoNT/A is able to 
inhibit the occurrence of inflammatory process when injected prior to painful stimulus [62,66,71,72]. 
BoNT/A was able to reduce neuropathic symptoms only after neuropathy was already established but 
was  unable  to  preventively  protect  against  the  onset  of  neuropathy.  If  BoNT/A  was  injected 
contralaterally to the lesion,  anti-allodynic  effects  were  not  observed [Figure 1(C)]—an  important 
point demonstrating the absence of a systemic diffusion in these experimental conditions. By using the 
same neuropathic pain model, authors observed that peripheral administration of BoNT/B did not exert 
antiallodynic effects  [90] [Figure 1(D)]. This  is in  agreement  with  previous research of the same 
authors showing different effects of the two serotypes in inflammatory pain models [66]. It should be 
remembered that usable doses of BoNT/B are lower than those of BoNT/A since the serotype B shows 
a higher toxicity, thus limiting its use [66,90]. Furthermore, Marinelli et al. [91] observed that BoNT/A 
significantly improved the functional recovery of the injured paw, as assessed in mice by the sciatic 
static index of functional recovery, examined through the footprint walking tracks of both ipsi- and 
contralateral paws [Figure 2(A)], and by the weight-bearing incapacitance test [Figure 2(B)].  Toxins 2010, 2  
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Figure 1. BoNT/A counteracts mechanical allodynia induced by chronic constriction injury 
(CCI) in mice. (A) Mechanical allodynia, expressed as withdrawal thresholds of applied 
force, of ipsi- and contralateral hindpaws as function of postoperative days in BoNT/A 
mice that received ipsi- and contralateral intraplantar injections of BoNT/A (15 pg/paw), 
either 5 (, ipsi;  , contra) or 12  (, ipsi;  , contra) days  after CCI. Contralateral 
hindpaw was injected to check for possible neuroparalytic effect of peripheral BoNT/A 
injection. (B) Withdrawal thresholds of ipsi- and contralateral hindpaws as  function of 
postoperative days after a intraplantar injections, into ipsi- and contralateral hindpaws, of 
BoNT/A 7.5 pg/paw (, ipsi; , contra) or BoNT/A 15 pg/paw (, ipsi; , contra) at  
day  5  after  CCI  (dashed).  (C)  Effect  of  a  single  intraplantar  injection  of  BoNT/A  
(,  15  pg/paw)  into  the  hindpaw  contralateral  to  the  injury.  Corresponding  ipsilateral 
hindpaws  were  injected  with  saline  ().  Injections  performed  at  day  5  (dashed).  
(D) Withdrawal thresholds of ipsi- and contralateral hindpaws as function of postoperative 
days  after  a  intraplantar  injections,  into  ipsi-  and  contralateral  hindpaws,  of  BoNT/B  
3.75 pg/paw (, ipsi; , contra) at day 5 after CCI (dashed). For (A-D), control curves of 
ipsi- () and contralateral () withdrawal thresholds in saline-injected hindpaws at day 5 
are reported for comparisons. Dashed lines represents the day of injection while day 0 
indicates the day of injury. For further details, see [89,91]. 
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Figure 2. BoNT/A improves the functional recovery in mice subjected to CCI. (A) Effect 
of intraplantar injection of saline () or 15 pg/paw BoNT/A () on the sciatic static index 
(SSI),  calculated  using  the  equation  published  in  [126].  The  hindpaw  parameters  to 
calculate SSI were obtained by walking track analysis and two footprint parameters were 
considered: the 1st–5th toe spread (TS) and the distance between the tip of the third toe and 
the most posterior aspect of the paw (PL). These variables were measured from at least five 
footprints, recorded on three different walking track runways, and entered into the sciatic 
static index-formula: SSI = +101.3 ×  (ITS-CTS) / CTS − 54.03 ×  (IPL-CPL) / CPL − 9.5. 
ITS: ipsilateral toe spread; CTS: contralateral toe spread; IPL: ipsilateral paw length; CPL: 
contralateral paw length. For SSI, a value of zero represents normal function and −100 
represents complete loss of function of the sciatic nerve. (B) Effect of intraplantar injection 
of saline () or BoNT/A 15 pg/paw () on weight bearing. Dashed line indicates the day 
of injection. Weight bearing was measured as percentage distribution  of weight on the 
ipsilateral hindpaw. Ipsi- and contralateral weight distributions were measured using an 
incapacitance tester as described in [91]. 
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In addition to behavioral effects, some interesting data are emerging about the ability of BoNT/A to 
interfere with regenerative processes after nerve injury. It is known that the capacity of regenerating 
tissue is present in the peripheral nervous system [92]. When neuropathy is induced in animals, a 
composite process occurs that, together with axonal degeneration, is associated with infiltration of cells 
of the immune system such as macrophages and glial cells [93]. Schwann cells (SC) also have an 
important  role  in  both  degenerative  and  regenerative  processes  [94]  and  their  interaction  with 
macrophages is a determinant to provide a favorable microenvironment to axonal sprouting, elongation 
and maturation [95]. Marked changes in different gene and protein expression in sensory neurons are 
associated  with  nerve  injury  and  the  consequent  process  related  to  nerve  regeneration.  Marinelli  
et al. [91] have observed a significantly higher level of Cdc2, a prototypical cyclin-dependent kinase 
that regulates the mitotic phase of the cell cycle [96] and the cell migration processes [97], in nerve 
samples from neuropathic mice treated with BoNT/A with respect to samples from saline-injected 
mice. A recent paper from Han and colleagues [98] provides insight into the mechanisms of nerve 
regeneration, showing a new function of Cdc2 and other Cdk family members in the nervous system. 
They demonstrated that following sciatic nerve injury, isolated SC show elevated Cdc2 expression and 
enhanced  migration  and  that  inhibition  of  Cdc2  can  block  this  effect,  whereas  increased  Cdc2 
expression enhances cell migration. As previously reported, SC play a role in injured nerves: they 
dedifferentiate to immature SC, acquire again the expression of molecules characteristic of embryonic 
development  and  up-regulate  cytoskeleton  constituents  such  as  glial  fibrillary  acidic  protein  
(GFAP)  [99].  They  regain  capacity  to  proliferate,  and  their  migration  facilitates  peripheral  nerve 
regeneration after injury. A gradually enhanced expression of SC markers such as S100β and GFAP, 
proteins  identifying  myelinating  and  non-myelinating  SC,  respectively,  also  expressed  in 
dedifferentiated cells, is observed after sciatic nerve injury [100–102]. This increase post-CCI is due to 
proliferative state of SC after injury. Marinelli  et  al. [91] demonstrated a role of BoNT/A in  the 
modulation of these regenerative processes and their relationship with SC, showing a further enhanced 
expression of these proteins after botulinum treatment.  
Mika  et  al.  [103]  have  added  insights  in  the  mechanism  of  action  of  BoNT/A,  investigating 
molecular changes occurring in DRG and spinal cord after CCI to the sciatic nerve in rats. They 
observed that in the ipsilateral lumbar spinal cord of neuropathic rats, SNAP-25, prodynorphin and 
microglial (C1q) marker mRNAs were upregulated, while no changes occurred in neuronal (NOS1) 
and inducible (NOS2) nitric oxide synthase, GFAP, proenkephalin and pronociceptin mRNAs. In the 
DRG, ipsilateral upregulation of prodynorphin, pronociceptin, NOS1, NOS2, C1q and GFAP mRNAs, 
downregulation  of  proenkephalin  and  no  changes  in  SNAP-25  mRNA  were  observed.  A  single 
intraplantar BoNT/A (75 pg/paw) injection induced long-lasting antinociception in the CCI model. 
BoNT/A diminished injury-induced ipsilateral spinal upregulation of SNAP-25 and C1q mRNAs and, 
in the ipsilateral DRG, reduced SNAP-25 and upregulated prodynorphin, pronociceptin and NOS1 
mRNAs, with a significant decrease of C1q-positive cell activation. These evidences demonstrate that 
peripheral  administration  of  BoNT/A  attenuates  neuropathic  pain-related  behavior  by  modulating 
several proteins in DRG and spinal cord, structures distant from the peripheral injection site. Silenced 
microglia/macrophages after BoNT/A administration could be secondary to the inhibition of neuronal 
activity, and such a decrease of neuroimmune interactions could be the key for a long-lasting BoNT/A 
effect in neuropathic pain.  Toxins 2010, 2  
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Trigeminal neuralgia is a neuropathic pain disorder characterized by recurrent episodes of intense, 
lancinating  pain  felt in  one or more divisions  of the trigeminal  distribution, whose onset may be 
spontaneous or due to stimulation of a trigger point on the face or in the oral cavity. An animal model 
of such pathology is the unilateral infraorbital nerve constriction (IoNC) in rats [104]. IoNC produces 
long-lasting neuropathy behavior, characterized by the head withdrawal to mechanical stimulation in 
the whiskers pad area, concomitant with faster onset and increased magnitude of transmitter release 
from somata of trigeminal ganglion (TRG). By using the IoNC pain model, Kitamura et al. [105] 
found  that  peripheral  injection  of  BoNT/A,  performed  three  days  postinjury,  alleviated  the  
IoNC-induced  neuropathy  behaviors  and  decreased  the  exaggerated  neurotransmitter  release  in 
neurons acutely isolated from TRG ipsilateral to IoNC; the anti-allodynic effect being maintained for 
at least two weeks.  
In  another  study,  Favre-Guilmard  et  al.  [73]  compared  different  commercial  preparations  of 
BoNT/A on mechanical hyperalgesia induced by paclitaxel in rats. This model mimics the induction of 
peripheral polineuropathy that follows chemotherapy, which represents a significant limiting problem 
in clinical therapy. In this research, the reliable bilateral mechanical hyperalgesia induced by repeated 
injections  of  paclitaxel  was  affected  by  the  injection  of  BoNT/A  that  produced  a  significant 
antihyperalgesic effect in the injected paw of neuropathic animals three days after administration. The 
effects of BoNT/A was also tested in an experimental diabetic neuropathy model in rats [106]. In this 
study, rats were made diabetic by a single intraperitoneal injection of streptozotocin, and developed 
hyperalgesic behavior in sensitivity to mechanical, thermal and chemical noxious stimuli; BoNT/A 
was effective in reducing hyperalgesia at day 5 after the peripheral toxin injection and 24 hours after 
intrathecal injection [107]. 
4.4. Other Pain Models 
BoNT/A  has  demonstrated  efficacy  in  relieving  pain  symptoms  also  of  inflammatory  arthritic  
pain [108]. Two murine models were considered: (i) the acute inflammatory arthritis produced by  
intra-articular injection of carrageenan and, (ii) the chronic inflammatory arthritis by intra-articular 
injection of Freund's complete adjuvant (CFA) [109]. In these models, pain relief was assessed by 
tenderness  (evoked  pain  by  touching  the  affected  area)  measures  and  correlated  to  spontaneous 
nocturnal wheel-running. Narcotic analgesics were effective in both models, but in fully analgesic 
doses they impaired wheel-running activity. Intra-articular injection of BoNT/A significantly reduced 
arthritis joint tenderness, both in acute and chronic inflammatory arthritis, and normalized impaired 
spontaneous wheel running in mice with chronic inflammatory arthritis but not in those with acute 
inflammatory arthritis. These results suggest that intra-articular injection of BoNT/A is a promising 
therapy for chronic inflammatory arthritis but may not be effective for acute arthritis pain. 
The  post-surgical  pain  is  a  type  of  intense  pain  affecting  nearly  50%  of  patients  subjected  to 
surgical operations. As with other kinds of pain, also post-surgical pain is treated with opioid and  
non-opioid drugs, but it often persists and gives rise to primary and secondary hyperalgesia. The most 
common  experimental  approach  to  study  postsurgical  hyperalgesia  is  the  incisional  model  of 
pain [110]. Diverse drugs reduce incision-induced mechanical hyperalgesia in rats, but only morphine 
has been proven to be 100% effective, however beneficial effects last only for a few hours. Filipovic  Toxins 2010, 2  
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et al. [111] reported that a single subcutaneous injection of BoNT/A into plantar surface of the injured 
hindpaw, completely abolished secondary hyperalgesia after gastrocnemius incision in rats. What is 
more interesting, is that a single injection was enough to induce antihyperalgesic effects and that these 
effects lasted for at least 10 days starting from day 5 after injection.  
5. BoNT/A-Induced Analgesia: A Closer Look 
All the evidence in favor of analgesic properties of BoNT/A in a wide variety of pain models pose 
some  interesting  questions  about  the  mechanism  of  action.  In  the  recent  years,  two  main  points 
emerged about the effects of botulinum neurotoxins: the first one is that these molecules are effective 
not only in peripheral but also in the central nervous system. The second important point is that part of 
the effects induced by BoNT/A administration are observable distant from the site of injection.  
Under therapeutic treatment of muscle hyperactivity conditions, BoNT/A is locally applied, with 
little or absent diffusion, and its paralyzing action remains confined to the nerve-muscle junction, close 
to  the  injection  site.  This  assumption  constituted  a  ―dogma‖  for  many  years  of  the  use  of  these 
neurotoxins  in  human  therapy.  Some  experimental  evidence  obtained  in  recent  years  from  basic 
scientific research challenge this dogma and raise concern that while most of the effects are localized 
close to the injection site, BoNT/A can also act at distant sites. Actually, the possibility that BoNT/A 
could reach the CNS by retrograde transport was already suggested many years ago by experiments 
with radiolabeled BoNT/A [112,113]; however, it was observed that the retrograde axonal transport 
was so slow that the toxin was likely to be inactivated before it reached the cell soma [114]. 
More  recent  studies  support  the  retrograde  transport  of  BoNT/A.  In  particular,  Antonucci  
et  al.  [115]  demonstrated  that  BoNT/A  may  be  retrogradely  transported  by  central  neurons  and 
motoneurons  and  then  transcytosed  to  afferent  synapses.  In  their  very  elegant  work,  the  authors 
presented three pieces of evidence in favor of axonal migration of BoNT/A. First, they showed that 
after a unilateral intrahippocampal injection of BoNT/A, cleaved SNAP-25 was detectable also in the 
contralateral untreated hemisphere. Second, after injection of BoNT/A into the optic tectum, cleaved 
SNAP-25 appeared also in synaptic terminals within the retina. Since the natural target of BoNT/A is 
the neuromuscular junction, in a third experiment, authors chose to test the spread of toxin in the facial 
motoneurons projecting to the whisker muscles. After BoNT/A injection at the center of the whisker 
pad, cleaved SNAP-25 was detected in the facial nucleus, confirming a possible migration of toxin also 
along  motoneurons.  Summarizing,  after  BoNT/A  injection  into  central  and  peripheral  regions, 
truncated SNAP-25—the target protein of SNARE complex selectively cleaved by BoNT/A—appeared 
not only at the injection site but also in distant regions projecting to the infusion area. The retrograde 
spread was blocked by the microtubule depolymerizing agent colchicine, pointing to an involvement of 
microtubule-dependent  axonal  transport.  In  another  research,  when  BoNT/A  was  injected  in  the 
whisker pad area, Kitamura et al. [105] observed a strong inhibition of the increased KCl-evoked 
neurotransmitter release from trigeminal ganglion neurons after infraorbital nerve constriction. 
Similarly  to  Antonucci  et  al.  [115],  the  results  reported  in  another  study  [116]  may  not  be 
completely accounted for without considering a possible axonal transport of the toxin distant from the 
injection site. Bach-Rojecky and Lackovic [116] used the model of unilateral injection of acidic saline 
solution into gastrocnemius muscle as an animal model of muscle hyperalgesia. In this model, both ipsi Toxins 2010, 2  
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and  contralateral  hyperalgesia  are  detectable,  with  contralateral  hyperalgesia  being  considered  as 
centrally mediated secondary hyperalgesia. BoNT/A, subcutaneously injected into ipsilateral hindpaw, 
exerted antihyperalgesia both on ipsi- and contralateral hindpaws. The effect on both sides was evident 
on day 5 and was of similar intensity. Interestingly, when colchicine was injected into ipsilateral sciatic 
nerve, one day before the ipsilateral BoNT/A injection, the antihyperalgsic effect of BoNT/A on both 
sides was not observed. On the contrary, if colchicine was injected into contralateral side, opposite to 
the site of pain induction and BoNT/A injection, it did not prevent the antihyperalgesic effects of 
BoNT/A on both sides. Finally, when BoNT/A was applied intrathecally, the bilateral hyperalgesia 
was also reduced. Altogether, these results cannot be explained without the involvement of the central 
nervous system and without the assumption that BoNT/A is transported from the site of injection. 
Bilateral effects after unilateral BoNT/A injection were also observed in paclitaxel-induced neuropathy 
in rats [73], and in streptozotocin induced diabetic neuropathy in rats [107].  
Even  if  an  easy  generalization  of  the  results  derived  from  animal  studies  to  humans  is  not 
recommended and a number of factors (anatomical differences, doses, volume of dilution, etc.) have to 
be  taken  into  account  (see  [117]),  these  studies  represent  a  crucial  step  in  the  comprehension  of 
botulinum neurotoxin transport mechanism. 
6. Proposed Mechanism of Action for BoNT/A Analgesia  
Considering all the results reviewed, we suggest a possible model of action of BoNT/A on pain 
transmission,  as  in  the  scheme  depicted  in  Figure  3.  In  this  scheme,  two  pain  conditions  are 
considered: inflammatory, such as that induced by chemicals (formalin, capsaicin, etc.) or neuropathic 
pain  derived  from  nerve  injury  (CCI  and  spinal  nerve  ligation  or  transection).  BoNT/A  may  be 
administered  peripherally  by  subcutaneous  or  intraplantar  injections,  or  centrally  by  intrathecal  or 
intracerebroventricular injections. Depending on the site of injection, BoNT/A may differently exert its 
effects. By inhibiting the release of neurotransmitter and/or neuropeptides from nociceptive endings, 
peripherally  injected  BoNT/A  may  reduce  directly  the  peripheral  sensitization  and  indirectly  the 
central sensitization, (Figure 3, point 1). In the same way, intrathecally injected BoNT/A may inhibit 
the release of neurotransmitters and/or neuropeptides from central terminals of nociceptive afferents, 
reducing the central sensitization (Figure 3, point 2). Finally, peripherally injected BoNT/A may be 
retrogradely transported along axons of peripheral nerves, thus acting also on central sensitization 
processes (Figure 3, point 3). This retrograde transport may be responsible for the displacement of 
peripheral injected BoNT/A at the level of the spinal dorsal horn where it exerts a possible inhibition 
of spinal release of neurotransmitters. Moreover, in a neuropathic pain model, the retrograde transport 
of BoNT/A, after being peripherally injected at the level of the paw, may be involved in the observed 
regenerative processes at the level of injured nerve [91] and the inhibitory effects at level of DRG and 
spinal cord [103].  
Whatever the mechanism, the analgesic effects observed, as well as the lack of deleterious side 
effects, imply that, while experimental research is going to continue, the potential use of BoNT/A for 
therapy is strongly supported. 
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Figure 3. Proposed mechanism of action of BoNT/A in pain modulation. In this scheme, 
the analgesic effects of BoNT/A is thought to be exerted through the inhibition of the 
release  of  neurotrasmitters  and/or  neuropeptides  from  nociceptive  neurons  both  at 
peripheral and/or central level, depending on the route of administration. (1) The peripheral 
analgesic effect of BoNT/A, as observed after subcutaneous or intraplantar injection, may 
be  a  direct  consequence  of  the  reduced  release  of  neuromodulators  from  nociceptive 
endings. By inhibiting this release, peripherally injected BoNT/A may reduce directly the 
peripheral sensitization. (2) When intrathecally injected, BoNT/A may inhibit the release of 
neurotransmitters  and/or  neuropeptides  from  central  terminals  of  nociceptive  afferents 
reducing the central sensitization. (3) Central analgesic effects may be also induced by 
retrograde transport along axons of peripherally injected BoNT/A. These peripheral and 
central effects may occur, and partially overlap between them, both in inflammatory and 
neuropathic pain models. Symbols: AMPA, 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl) 
propanoic  acid  receptors  of  glutamate;  BDNF,  brain  derived  neutrophic  factor;  CCI, 
chronic  constriction  injury;  CGRP,  calcitonin  gene  related  protein;  CRLR,  calcitonin-
receptor like receptor; DRG, dorsal root ganglions; Glu, glutamate; mGluR, metabotropic 
glutamate  receptors;  NK1,  neurokinin  1  receptors;  NMDA,  N-methyl-D-Aspartate 
receptors of gluatamate; SNT, spinal nerve transection; SP, substance P; TrkB, tyrosin 
kinase B receptors. 
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7. Conclusions and Future Perspectives 
In  summary,  BoNTs  are  zinc  metalloendoproteases  that  exhibit  extraordinary  specificities  for 
proteins involved in the neurotransmitter release process, whose toxicity makes them responsible for 
animal  and  human  botulism.  However,  these  extremely  poisonous  molecules  can  become  useful 
therapeutic agents in a number of expanding applications in human medicine, including modulation 
and alleviation of pain conditions. This is particularly evident for one of the BoNTs serotypes, the 
serotype  A.  One  of  the  reasons  for  this  success  is  the  evident  advantage  of  using  a  drug  with  a 
prolonged duration of action, thus allowing a long interval between treatments, as demonstrated by all 
the studies reviewed in this present review.  
Another important aspect is that a single injection of BoNT/A is able to induce long-term analgesic 
effects in many different pain models, from inflammatory to neuropathic. The indications for BoNTs 
therapy will, no doubt, continue to expand and ongoing efforts to elucidate BoNTs‘ mechanisms of 
action  for  reducing  pain  will  provide  an  essential  foundation  for  developing  future  therapeutic 
strategies. Although BoNTs may benefit pain syndromes and can theoretically be administered to treat 
many pain conditions, its use appears restricted to peripheral administration and the possible lethal 
consequences of systemic administration of the toxin limit its potential for clinical trials. It should be 
recognized  that  peripheral  administration  is  also  not  completely  devoid  of  risk  and  needs  further 
investigations, with particular reference to the central action. Much evidence has been presented for 
retrograde transport of BoNT/A distant from the site of injection and more in depth studies will be 
necessary to characterize the mechanisms of this retrograde transport. Among others, as suggested by 
Caleo et al. [118], an important aspect that has to be better clarified is whether the central effects 
depend on the dose used as well as on density of innervations and levels of expression of toxin receptors. 
In  an  attempt  to  bypass  the  risks  due  to  toxicity,  a  desirable  characteristic  for  future  BoNTs 
products would be an increased specificity for pain conditions. This may be achieved by replacing the 
native binding domain with another protein to re-direct the light chain to a different nerve or cell [119]. 
Such modifications may enable BoNTs to treat pain without engendering weakness of nearby muscles. 
In this context, an innovative class of biopharmaceuticals obtained by recombinant techniques has 
been recently proposed  [120–125]. These recombinant  proteins,  also  named as  ―targeted secretion 
inhibitors‖, incorporate the light  chain  fragment of BoNT/A expressing the endopeptidase activity 
fused with a protein that selectively binds to specific neuronal or non-neuronal cells. A promising 
example of these proteins is the recombinant protein obtained by fusion of the light chain of BoNT/A 
with lecitin from Erythrina cristagalli, which binds to galactose-containing carbohydrates selectively 
present on nociceptive afferents in the central and peripheral nervous system. This recombinant protein 
has been demonstrated to be effective in inhibiting the release of SP and glutamate from DRG neurons 
in culture [122] and to relieve pain symptoms in different pain models [123].  
Since BoNT/A is actually under clinical trials for treatment of pain in various types of headache and 
migraine  conditions  [57],  the  translation  of  encouraging  results  from  preclinical  studies  in 
inflammatory and neuropathic animal pain models, to clinical treatments of chronic pain in humans 
can  be  considered  a  crucial  step  for  human  health.  However,  more  in  depth  researches  are  still 
necessary to better establish the exact mechanism responsible for analgesic effects of BoNT/A. This 
will improve our knowledge about this relevant thematic of research and ongoing efforts to elucidate Toxins 2010, 2  
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BoNTs‘ mechanisms of action for reducing pain will provide an essential foundation for developing 
future therapeutic strategies. 
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